The Therapeutic Goods Administration (TGA) is seeking feedback on options to improve the Therapeutic Goods Advertising Code (No.2) 2018 (the Code). The Code is the compliance standard that prescribes the minimum requirements for the lawful advertising of therapeutic goods to the general...More
Health services funded under the Indigenous Australians’ Health Programme (IAHP) collect and supply important Indigenous health data sets to the Department of Health as part of their funding agreements. These are the:
Aboriginal and Torres Strait Islander National Key Performance...More
On 25 February 2021, changes to the Therapeutic Goods (Medical Devices) Regulations 2002 (‘the Regulations’) commenced to introduce a new regulatory framework (the Framework) for medical devices that are designed and manufactured for individual patients (otherwise known as 'personalised'...More
Scheduling amendments referred to expert advisory committee
This consultation is for applications and delegate initiated proposals to amend the Poisons Standard. The scheduling amendments and any submissions received will be considered at the June 2021 meeting of the ...More
From 25 February 2021, a new framework for regulating software as a medical device will commence. The Regulation of software based medical devices details these changes, and additionally the following guidance documents have also been published to assist users understand the various...More
There are currently three medicines available for the treatment of opioid dependence under the Pharmaceutical Benefits Scheme (PBS)
Opiate Dependence Treatment Program (ODTP). These medicines are buprenorphine (tablets and modified release injections), buprenorphine with naloxone...More
Scheduling amendments referred to expert advisory committee
This consultation is for applications and delegate initiated proposals to amend the Poisons Standard. The scheduling amendments and any submissions received will be considered at the June 2021 joint meeting of the ...More
Scheduling amendments referred to expert advisory committee
This consultation is for applications and delegate initiated proposals to amend the Poisons Standard. The scheduling amendments and any submissions received will be considered at the June 2021 meeting of the ...More
CONTENT WARNING
The Department of Health acknowledges the devastating effects associated with acts of self-harm on individuals, their families, friends and communities. This consultation relates to information on self-poisonings that some people may find distressing. If you, or someone you...More
The Therapeutic Goods Administration (TGA) is seeking feedback on a proposal to remake some of the legislative instruments relating to human cell and tissue (HCT) products (including blood and blood components), which sunset in October 2021.
We are seeking feedback to make sure the...More
Scheduling amendments referred to expert advisory committee
This consultation is for applications to amend the Poisons Standard in relation to substances used in oral contraceptives. The scheduling proposals, and any submissions received, will be considered at the June 2021...More
The Efficient Funding of Chemotherapy (EFC) Program provides funding for chemotherapy medicines used for the treatment of cancer that are administered through infusion or injection at public or private hospitals. Not all chemotherapy medicines are provided through the EFC Program, but may be...More
On 14 August 2020, the Hon Mark Coulton, Minister for Regional Health, Regional Communications and Local Government, announced a review into the Hearing Services Program.
An Independent Expert Panel comprising Professor Mike Woods (Chair) and Dr Zena Burgess is conducting the Review. The...More
Introduction
In November 2019 the Australia and New Zealand Ministerial Forum on Food Regulation endorsed an ambitious plan to reform the Bi-national Food Regulation System to ensure it remains strong, robust and agile into the future. A...More
The Therapeutic Goods Administration (TGA) is seeking comments from interested parties on the addition of proposed new advisory statements for labels of over the counter (OTC) and registered complementary medicines containing menthol for dermal use, for inclusion in the Required...More
The Therapeutic Goods Administration (TGA) is seeking comments from interested parties on changes to current requirements for advisory statements for labels of non-prescription medicines containing antihistamines indicated for short term use in insomnia (diphenhydramine, doxylamine and...More
The Therapeutic Goods Administration (TGA) is seeking comments from interested parties on addition of a proposed new required advisory statement for labels of non-prescription medicines containing more than 1.5 per cent lidocaine (lignocaine) for topical oral use, for inclusion in the ...More
The Therapeutic Goods Administration (TGA) is seeking comments from interested parties on proposed new advisory statements for labels of over the counter (OTC) and registered complementary medicines containing methyl salicylate for dermal use , for inclusion in the Required...More
The Therapeutic Goods Administration (TGA) is seeking feedback on proposals to help ensure ongoing, reliable supply of important medicines.
Medicine shortages have been of particular concern during the COVID-19 pandemic. We have been reviewing the ways in which we can better assist...More
This form is to completed if you wish to complete a request for a revalidated service for a client with the Australian Government Hearing Services Program.
Please click the link below to begin your request.
DISCLAIMER
This is a draft form for testing purposes only. The form...More
The Medical Research Future Fund’s (MRFF) Cardiovascular Health Mission (the Mission) was announced as part of the 2019-20 budget to provide $220 million for research to make transformative improvements in cardiovascular health and stroke for all Australians.
An Expert Advisory Panel was...More
The Medical Research Future Fund’s (MRFF) Traumatic Brain Injury Mission (the Mission) was announced as part of the 2019-20 budget to provide $50 million for research to improve patient recovery after Brain injury. It will support projects that predict recovery outcomes, or identify the most...More
The Medical Research Future Fund’s (MRFF) Genomics Health Futures Mission (the Mission) was announced as part of the 2018-19 budget to provide $500 million for research to deliver better testing, diagnosis and treatment.
An Expert Advisory Committee was appointed in April 2019 to provide...More
The Medical Research Future Fund’s (MRFF) Stem Cell Therapies Mission (the Mission) was announced as part of the 2019-20 budget to provide $150 million for research to develop innovative, safe and effective treatments accessible to all Australians who need them.
An Expert Advisory Panel ...More
The Medical Research Future Fund’s (MRFF) Dementia, Ageing and Aged Care Mission (the Mission) was announced in December 2018 to provide $185 million for research to support older people to maintain their health and quality of life as they age, live independently for longer and access quality...More
The Medical Research Future Fund’s (MRFF) Indigenous Health Research Fund (IHRF) was announced in February 2019 to provide $160 million for research to improve the health of Aboriginal and/or Torres Strait Islander people.
An Expert Advisory Panel was appointed in September 2019 to...More
Preventive health is a key pillar of Australia’s Long Term National Health Plan with mental health.
In June 2019, the Minister for Health, the Hon Greg Hunt MP announced that the Australian Government would develop a 10-year National Preventive Health Strategy (the...More
The Australian Government, through the Critical Technologies Policy Coordination Office (CTPCO), is undertaking consultation on the future of critical technologies in the Australian agriculture and health sectors. Critical technologies are current and emerging technologies...More
The Australian Government is undertaking a significant program of reform to the regulation of therapeutic goods in Australia. As part of the Australian Government Department of Health, the Therapeutic Goods Administration (TGA) regulates therapeutic goods, and is responsible for implementing...More
The Therapeutic Goods Administration (TGA) is seeking comments on a proposed standard for vaporiser nicotine products.
Vaporiser nicotine products are nicotine-containing products intended to be used in vaping devices such as e-cigarettes, e-cigars and other electronic nicotine...More